Skip to main content
ORNL’s green solvent enables environmentally friendly recycling of valuable Li-ion battery materials. Credit: Andy Sproles/ORNL, U.S. Dept. of Energy

Scientists at Oak Ridge National Laboratory have developed a solvent that results in a more environmentally friendly process to recover valuable materials from used lithium-ion batteries, supports a stable domestic supply chain for new batteries

Belinda Akpa applies her diverse expertise and high-performance computing to accelerate the drug discovery process and increase the chances of success when candidate molecules go to clinical trials. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.

The proposed Battery Identity Global Passport suggests a scannable QR code or other digital tag affixed to Li-ion batteries to identify materials for efficient end-of-life recycling. Credit: Andy Sproles, ORNL/U.S. Dept. of Energy

Scientists at Oak Ridge National Laboratory have devised a method to identify the unique chemical makeup of every lithium-ion battery around the world, information that could accelerate recycling, recover critical materials and resolve a growing waste stream.

ATOM logo

The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.  

ORNL recognized the small businesses that have made a positive impact on ORNL’s operations at the virtual 2020 Small Business Awards. Credit: ORNL, U.S. Dept. of Energy

Thirty-two Oak Ridge National Laboratory employees were named among teams recognized by former DOE Secretary Dan Brouillette with Secretary’s Honor Awards as he completed his term. Four teams received new awards that reflect DOE responses to the coronavirus pandemic.

Fungi use signaling molecules called LCOs to communicate with each other and to regulate growth. Credit: Jessy Labbe/Oak Ridge National Laboratory, U.S. Dept. of Energy

Oak Ridge National Laboratory and collaborators have discovered that signaling molecules known to trigger symbiosis between plants and soil bacteria are also used by almost all fungi as chemical signals to communicate with each other.

Frontier supercomputer

A multi-institutional team, led by a group of investigators at Oak Ridge National Laboratory, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease. The feat has earned the team a finalist nomination for the Association of Computing Machinery, or ACM, Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.